Success Metrics

Active Trials
4(80%)

Phase Distribution

Ph phase_1
3
60%
Ph phase_2
2
40%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting4
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
4
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

not_yet_recruiting120%
recruiting480%

Recent Activity

4 active trials
Showing 5 of 5
recruitingphase_2

A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

NCT07589244
not_yet_recruitingphase_2

Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

NCT07486310
recruitingphase_1

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

NCT07093814
recruitingphase_1

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

NCT06368921
recruitingphase_1

A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors

NCT06826313

Clinical Trials (5)

Showing 5 of 5 trials
NCT07589244Phase 2

A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

Recruiting
NCT07486310Phase 2

Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Not Yet Recruiting
NCT07093814Phase 1

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

Recruiting
NCT06368921Phase 1

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

Recruiting
NCT06826313Phase 1

A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5